Nov 11, 2026

DEA TELEHEALTH PRESCRIBING FLEXIBILITY EXPIRES DECEMBER 31, WITH NO REPLACEMENT PUBLISHED YET

The temporary federal rule that lets clinicians prescribe Schedule II through V controlled substances by telehealth without a prior in-person visit expires at the end of December 31, 2026. The DEA sent its permanent special-registration rule to the White House review office on August 25, and it was still under review as of November 9, with no fifth extension published as of November 11. If nothing is published before the deadline, the Ryan Haight Act's in-person evaluation requirement returns on January 1, 2027, so clinics that prescribe controlled substances by telehealth should have an in-person plan ready. A separate permanent rule for buprenorphine treatment by telehealth, in effect since December 31, 2025, is not affected.

Sources: Island Insurance Group, November 11, 2026, https://islandinsurancegroup.com/dea-telehealth-prescribing-deadline-2026/ ; DNP Consulting, November 9, 2026, https://www.dnpconsulting.org/post/dea-s-telemedicine-prescribing-proposal-and-how-prescribers-can-push-back

Jobs

All jobs

News

All news